RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Molecular Pharmacology (USA) - Stock

Molecular Pharmacology (USA) Equity 2024

Molecular Pharmacology (USA) Equity

0 USD

Ticker

MLPH

ISIN

US60852T1097

WKN

A0HHDZ

In 2024, Molecular Pharmacology (USA)'s equity was 0 USD, a 0% increase from the 0 USD equity in the previous year.

Molecular Pharmacology (USA) Aktienanalyse

What does Molecular Pharmacology (USA) do?

The company Molecular Pharmacology (USA) Ltd is a biotechnology company based in the United States that specializes in the research and development of innovative drugs for the treatment of diseases. It was founded in Illinois in 2000 and has since been headquartered in Lincolnshire, Illinois. Molecular Pharmacology (USA) Ltd focuses on producing high-quality pharmaceutical agents that work at the molecular level and target specific objectives. Using advanced technologies such as computer-aided drug design (CADD) and high-throughput screening (HTS), the company identifies new drug candidates that specifically target certain diseases. The main focus of Molecular Pharmacology (USA) Ltd is the development of drugs for the treatment of cancer, inflammation, and metabolic diseases. In recent years, the company has also focused on other diseases, such as neurological disorders. Molecular Pharmacology (USA) Ltd divides its offerings into various areas to meet the diverse needs of customers. One of these areas is the provision of active ingredients for the pharmaceutical industry. The company provides high-quality pharmaceutical agents that can be used by other companies for further drug development and production. Another area is the development of its own drugs that can be used to combat various diseases. Molecular Pharmacology (USA) Ltd focuses on the identification and development of new drug candidates that specifically target the causes of diseases and enable effective treatment. Molecular Pharmacology (USA) Ltd also offers services to support customers in the identification and characterization of drug candidates. Customers can rely on the company's experience and expertise to support them in the development of new drugs. Some of the key products of Molecular Pharmacology (USA) Ltd include small molecules, antibodies, peptides, and natural compounds. These provide a high level of efficacy and safety in combating various diseases and thus serve as an important foundation for the development of new drugs. In recent years, Molecular Pharmacology (USA) Ltd has also increased its investments in collaboration with other companies and research institutions. This aims to leverage synergies to jointly identify and develop new drug candidates. An example of this is the collaboration with universities and research institutions specializing in the study of certain diseases. In summary, Molecular Pharmacology (USA) Ltd is a renowned biotechnology company that specializes in the research and development of innovative drugs for the treatment of diseases. The company divides its offerings into various areas and provides services to other companies and research institutions. Molecular Pharmacology (USA) Ltd is thus an important player in the field of drug development and contributes to saving many lives. Molecular Pharmacology (USA) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Molecular Pharmacology (USA)'s Equity

Molecular Pharmacology (USA)'s equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Molecular Pharmacology (USA)'s equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Molecular Pharmacology (USA)'s equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Molecular Pharmacology (USA)'s equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Molecular Pharmacology (USA)’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Molecular Pharmacology (USA) Stock

What is the equity of Molecular Pharmacology (USA) this year?

Molecular Pharmacology (USA) has equity of 0 USD this year.

What was the equity of Molecular Pharmacology (USA) compared to the previous year?

The equity of Molecular Pharmacology (USA) has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Molecular Pharmacology (USA)?

A high equity is advantageous for investors of Molecular Pharmacology (USA) as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Molecular Pharmacology (USA)?

A low equity can be a risk for investors of Molecular Pharmacology (USA), as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Molecular Pharmacology (USA) affect the company?

An increase in equity of Molecular Pharmacology (USA) can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Molecular Pharmacology (USA) affect the company?

A reduction in equity of Molecular Pharmacology (USA) can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Molecular Pharmacology (USA)?

Some factors that can affect the equity of Molecular Pharmacology (USA) include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Molecular Pharmacology (USA) so important for investors?

The equity of Molecular Pharmacology (USA) is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Molecular Pharmacology (USA) take to change the equity?

To change equity, Molecular Pharmacology (USA) can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Molecular Pharmacology (USA) pay?

Over the past 12 months, Molecular Pharmacology (USA) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Pharmacology (USA) is expected to pay a dividend of 0 USD.

What is the dividend yield of Molecular Pharmacology (USA)?

The current dividend yield of Molecular Pharmacology (USA) is .

When does Molecular Pharmacology (USA) pay dividends?

Molecular Pharmacology (USA) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Pharmacology (USA)?

Molecular Pharmacology (USA) paid dividends every year for the past 0 years.

What is the dividend of Molecular Pharmacology (USA)?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Pharmacology (USA) located?

Molecular Pharmacology (USA) is assigned to the '-' sector.

Wann musste ich die Aktien von Molecular Pharmacology (USA) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Pharmacology (USA) from 7/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did Molecular Pharmacology (USA) pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Molecular Pharmacology (USA) in the year 2023?

In the year 2023, Molecular Pharmacology (USA) distributed 0 USD as dividends.

In which currency does Molecular Pharmacology (USA) pay out the dividend?

The dividends of Molecular Pharmacology (USA) are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Molecular Pharmacology (USA)

Our stock analysis for Molecular Pharmacology (USA) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Pharmacology (USA) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.